White Peony Root and Liver Protection

Liver Protection — scientific infographic poster

“Liver support” is one of the most heavily marketed claims in the supplement world, and white peony root — Radix Paeoniae Alba, Bai Shao, the boiled and peeled root of Paeonia lactiflora — gets pulled into it regularly. There is a real scientific literature behind the claim. It is also, honestly, much weaker than the evidence for peony extract in rheumatoid arthritis, and this page starts by saying so rather than burying it.

What follows is the actual state of play: what the animal and cell studies show, what the one clinically interesting human observation is, why oral bioavailability complicates the whole story, and what genuinely protects a liver.

Table of Contents

  1. The Verdict, Stated First
  2. The “Liver” in Traditional Terms Is Not the Organ
  3. What “Hepatoprotective” Means in a Study
  4. The Animal and Cell Evidence
  5. The Paeoniflorin Mechanism
  6. The Human Data: TGP and Drug-Related Liver Enzymes
  7. The Bioavailability Problem
  8. The Mirror-Image Risk: Herbs That Damage Livers
  9. What Actually Protects a Liver
  10. Forms, Doses and Label Reading
  11. Cautions and Contraindications
  12. Key Research Papers
  13. Connections
  14. Featured Videos

The Verdict, Stated First

White peony root and its purified constituent paeoniflorin show consistent protective effects against experimental liver injury in rodents and in cultured liver cells. That body of work is substantial, reproducible across several different injury models, and mechanistically coherent.

It is also almost entirely preclinical. There is no large, well-controlled human trial showing that taking peony root or peony extract improves the course of any liver disease. The one human observation with genuine clinical interest is indirect: within the rheumatoid arthritis literature, adding Total Glucosides of Paeony to methotrexate has repeatedly been associated with fewer liver-enzyme abnormalities. That is a real and repeated finding, but it comes from trials designed to study arthritis, not liver disease, and mostly from a single country.

So: a promising laboratory story, an interesting side observation in arthritis patients, and nothing that would justify treating liver disease with a peony capsule. Abnormal liver enzymes have a cause, and finding that cause is what opens the way to treating it.

The “Liver” in Traditional Terms Is Not the Organ

A large part of the confusion here is a translation problem that nobody warned you about.

Classical descriptions of white peony root say it “softens the liver” and is used in formulas for “liver qi stagnation” Xiao Yao San and Si Ni San being the standard examples. Read in English, that sounds like a hepatology claim. It is not. In classical Chinese medicine the 肝 (gan) system is a functional category covering the smooth flow of emotion, tension in muscles and tendons, menstrual regulation, and eye symptoms. Its clinical picture — irritability, tightness, sighing, premenstrual tension — does not correspond to hepatitis, fatty liver or cirrhosis.

So when a marketing page cites “traditionally used to support the liver,” it is quoting a claim about a functional system, not about the organ that filters your blood. This is not a criticism of the tradition; it is a warning about the translation. Nothing in the classical literature amounts to evidence for treating hepatitis or fatty liver disease with peony.

What “Hepatoprotective” Means in a Study

Almost every hepatoprotection study follows the same design, and knowing it lets you read any of them:

  1. Take a rodent, or a dish of liver cells.
  2. Give it a known liver poison — carbon tetrachloride, high-dose paracetamol, D-galactosamine with bacterial endotoxin, concanavalin A (an immune-mediated hepatitis model), alcohol, or a fat-loaded diet.
  3. Give some animals the test compound, usually before or alongside the poison.
  4. Measure liver-enzyme leakage into blood (alanine aminotransferase (ALT) and aspartate aminotransferase (AST)), plus markers of oxidative stress and inflammation, plus how the liver looks under a microscope.

Three limitations are structural, and they apply to every herb marketed as liver-protective, not just this one:

The Animal and Cell Evidence

With those caveats in place, here is what the literature reports for peony and paeoniflorin. The consistency across different injury models is the genuinely notable part.

ModelWhat it representsReported effect
Carbon tetrachlorideFree-radical chemical injury; the classic fibrosis modelLower alanine aminotransferase/aspartate aminotransferase, less necrosis, less fibrosis on repeated dosing
Paracetamol (acetaminophen) overdoseGlutathione-depleting drug injuryReduced injury markers and oxidative stress
D-galactosamine + endotoxinInflammation-driven hepatitisReduced inflammatory cytokines and liver damage
Concanavalin AT-cell-mediated, immune hepatitis — the closest model to autoimmune hepatitisReduced immune-mediated injury; fits paeoniflorin’s immunomodulatory profile
Alcohol feedingAlcohol-related liver injuryReduced fat accumulation and injury markers
High-fat dietFatty liver disease (metabolic dysfunction-associated steatotic liver disease (MASLD)/non-alcoholic fatty liver disease (NAFLD))Less hepatic fat, improved insulin-related measures
Bile duct ligation / fibrosis modelsScarring from chronic obstructionReduced fibrosis markers and stellate-cell activation

The immune-hepatitis result is the most interesting one, because it is the model that best matches what paeoniflorin appears to do elsewhere. This is not a compound that looks like a general antioxidant; it looks like an immune modulator that happens to help most in injuries with a strong immune component.

The Paeoniflorin Mechanism

Four threads run through the mechanistic literature. All rest on cell and rodent work.

1. Damping inflammatory signalling. Paeoniflorin reduces activation of NF-κB, the master switch that turns on inflammatory genes, and lowers production of tumor necrosis factor-α, interleukin-1 beta (IL-1β) and interleukin-6 (IL-6). In the liver, much of the damage in hepatitis is done not by the original insult but by the immune response to it — the fire brigade breaking down the door. Turning down that response reduces collateral damage.

2. Supporting antioxidant defences. Reported effects include preservation of glutathione, the liver’s primary detoxification thiol, and increased activity of superoxide dismutase and catalase. Several studies implicate the Nrf2 pathway, the cell’s own antioxidant-gene programme — meaning the effect is less “peony mops up free radicals” and more “peony tells the cell to make its own mops.”

3. Reducing programmed cell death. Paeoniflorin has been reported to reduce hepatocyte apoptosis in injury models, with effects on the usual apoptotic machinery.

4. Anti-fibrotic effects. Liver scarring is driven by hepatic stellate cells, which transform from quiet fat-storing cells into collagen factories under TGF-β signalling. Paeoniflorin has been reported to interfere with stellate-cell activation and TGF-β/Smad signalling in animal fibrosis models. If this held in humans it would be genuinely important, because there is no approved anti-fibrotic drug for most liver disease. It has not been shown to hold in humans.

The Human Data: TGP and Drug-Related Liver Enzymes

The one human observation worth taking seriously comes from a completely different field. In the rheumatoid arthritis literature — where Total Glucosides of Paeony (TGP), a standardized extract of roughly 40 percent or more paeoniflorin, is an approved Chinese prescription drug at 600 mg two to three times daily — multiple trials and pooled analyses have reported that patients taking TGP alongside methotrexate, usually combined with leflunomide, had fewer liver-enzyme elevations than those on the same drugs without TGP.

Methotrexate raising alanine aminotransferase and aspartate aminotransferase is a routine clinical nuisance that causes dose reductions and treatment interruptions, so a genuine protective effect would matter. The signal has been reported repeatedly, and it fits the animal data.

The numbers behind it:

Then note what it is not:

A second drug, not methotrexate, shows the same signal. In a 2017 double-blind, placebo-controlled trial of 108 people with moderate-to-severe plaque psoriasis, all taking the psoriasis drug acitretin for 12 weeks, the liver enzyme ALT rose in 6.25% of those also given TGP versus 20.4% of those given placebo. It is still a blood-test result from a trial designed for skin disease, not a liver outcome.

Beyond this, there are Chinese reports of TGP or peony-containing formulas used in chronic hepatitis and other liver conditions, but the trials are small, heterogeneous, and generally use multi-herb products in which peony is one ingredient among many. That is not a foundation for a recommendation.

The Bioavailability Problem

Here is the technical wrinkle that most “peony protects the liver” articles skip.

Paeoniflorin is a glucoside — a molecule with a sugar attached — and it is large and water-loving. Animal pharmacokinetic studies consistently report low oral bioavailability. In a 1995 rat study, only 3.2–3.8% of an oral dose of paeoniflorin (0.5–5 mg/kg) reached the bloodstream compared with the same dose injected into a vein, and after an oral dose of 5 mg/kg only 1.0% appeared unchanged in the urine within 48 hours. Most of an oral dose does not reach the bloodstream intact.

Instead, much of it is worked on by gut bacteria, which cleave the sugar and generate different metabolites that are absorbed in its place. So the compound circulating in your blood after a cup of peony decoction is not entirely the compound that was dropped onto the liver cells in a dish. Two consequences follow:

This does not mean oral peony does nothing — the arthritis trials suggest something reaches its target, whether as paeoniflorin or as a metabolite. It does mean that any argument of the form “paeoniflorin protects liver cells in vitro, therefore peony capsules protect your liver” skips over the step where most of the compound never arrives.

The Mirror-Image Risk: Herbs That Damage Livers

An honest liver page has to say the uncomfortable part. Herbal and dietary supplements are now a leading cause of drug-induced liver injury in several countries, and the proportion of severe cases attributed to supplements has been rising in registry data. A 2017 review from a U.S. National Institutes of Health research symposium reported that supplement-induced liver injury now accounts for 20% of cases of liver toxicity in the United States in research data. The liver is the organ that processes everything you swallow, which makes it the organ most exposed to whatever is actually in the bottle.

White peony root itself is not a recognised common cause of liver injury, and it has a reassuring traditional and clinical safety record. But the risk in practice is rarely the named herb:

The same 2017 review found that most supplement-related liver injury in the United States comes from multi-ingredient products, and that the ingredient responsible is usually unknown or can only be suspected. Each added product is one more possible cause to sort through when liver enzymes are already raised. The U.S. National Institutes of Health (NIH) LiverTox database is the reference clinicians use for this.

What Actually Protects a Liver

Unglamorous and effective, in rough order of impact:

  1. Alcohol reduction. Nothing on any supplement shelf competes with this for anyone whose intake is above low-risk levels.
  2. Weight and metabolic health. Fatty liver disease (metabolic dysfunction-associated steatotic liver disease/non-alcoholic fatty liver disease) is the most common liver disease in most countries, and modest sustained weight loss — on the order of 7–10 percent of body weight — can reduce liver fat and inflammation. This is one of the few interventions with genuine biopsy-confirmed evidence: in a 2015 study of 293 people with biopsy-proven non-alcoholic steatohepatitis (NASH) on a 52-week lifestyle programme, everyone who lost 10% or more of their body weight had a lower disease-activity score on the repeat biopsy, 90% had resolution of NASH and 45% had regression of fibrosis.
  3. Hepatitis B and C. Hepatitis B vaccination prevents it; hepatitis C is now curable in most people with a short course of direct-acting antivirals. Both are massively underdiagnosed, and a blood test is how either is found — information no herb can provide.
  4. Paracetamol dosing. Staying within the maximum daily dose, and being aware that it is hidden inside combination cold and painkiller products, prevents a leading cause of acute liver failure.
  5. Medication review. Several common drugs affect liver enzymes; a pharmacist review is free and useful.
  6. Coffee. A genuinely interesting one: large observational studies consistently associate regular coffee consumption with lower rates of liver fibrosis, cirrhosis and liver cancer. A 2016 meta-analysis of nine studies (432,133 participants) found that each extra two cups of coffee a day was associated with a relative risk of cirrhosis of 0.56. Observational data cannot prove causation, but the consistency is striking and the intervention is harmless for most people.
  7. Investigating abnormal enzymes rather than supplementing over them. Raised alanine aminotransferase has a cause, and identifying that cause is what opens the way to treating it.

Forms, Doses and Label Reading

Each kind of peony product corresponds to a different piece of evidence — or to none.

ProductPaeoniflorin contentEvidence in a liver context
Total Glucosides of Paeony (TGP)≈40%+; prescription drug in ChinaThe only product with human data — and only as fewer methotrexate-related enzyme rises in arthritis patients
“White peony root” capsules≈1.6% (pharmacopeial minimum), often unstatedNone. Roughly a twenty-fifth the concentration of TGP
Traditional decoction, 6–15 g/day in a formulaCrude rootTraditional use only, and the traditional “liver” is not the organ
Multi-herb “liver support” blendsUsually undisclosedNone for peony specifically; adds attribution and interaction risk

The label details that let a product be matched to a study are: the species Paeonia lactiflora Pall.; the part and processing (root, peeled — Bai Shao / Radix Paeoniae Alba); a stated paeoniflorin percentage and milligram amount per dose; the phrase “total glucosides of paeony” if that is what is claimed; disclosed licorice content; and third-party testing with a certificate of analysis. A product that names no marker compound cannot be compared with any study, and “10:1 extract” is a manufacturing ratio, not a dose.

Cautions and Contraindications

Key Research Papers

Every numbered identifier below was checked live against NCBI E-utilities — author, title, journal and year all had to match before a PMID was printed. Where an identifier could not be confirmed that way, the entry keeps a PubMed topic search instead of a possibly incorrect number.

  1. Hepatoprotective effects of paeoniflorin in experimental liver injury — the core preclinical literature. PubMed search.
  2. Paeoniflorin in concanavalin A-induced immune-mediated hepatitis. PubMed search.
  3. Paeoniflorin, hepatic stellate cells and TGF-β/Smad signalling in liver fibrosis. PubMed search.
  4. Paeoniflorin, Nrf2 signalling and oxidative stress in the liver. PubMed search.
  5. Paeoniflorin in non-alcoholic fatty liver disease and high-fat-diet models. PubMed search.
  6. Xiang N, Li XM, Zhang MJ, et al. Total glucosides of paeony can reduce the hepatotoxicity caused by methotrexate and leflunomide combination treatment of active rheumatoid arthritis. International Immunopharmacology. 2015;28(1):802–807. — PubMed PMID: 26292180
  7. Zhou YX, Gong XH, Zhang H, Peng C. A review on the pharmacokinetics of paeoniflorin and its anti-inflammatory and immunomodulatory effects. Biomedicine & Pharmacotherapy. 2020;130:110505. — PubMed PMID: 32682112
  8. Intestinal bacterial metabolism of paeoniflorin and its metabolites. PubMed search.
  9. Navarro VJ, Khan I, Björnsson E, Seeff LB, Serrano J, Hoofnagle JH. Liver injury from herbal and dietary supplements. Hepatology. 2017;65(1):363–373. — PubMed PMID: 27677775
  10. Zhang W, Dai SM. Mechanisms involved in the therapeutic effects of Paeonia lactiflora Pallas in rheumatoid arthritis. International Immunopharmacology. 2012;14(1):27–31. — PubMed PMID: 22705050
  11. Kennedy OJ, Roderick P, Buchanan R, Fallowfield JA, Hayes PC, Parkes J. Systematic review with meta-analysis: coffee consumption and the risk of cirrhosis. Alimentary Pharmacology & Therapeutics. 2016;43(5):562–574. — PubMed PMID: 26806124
  12. Liu B, Meng X, Ma Y, et al. Clinical safety of total glucosides of paeony adjuvant therapy for rheumatoid arthritis treatment: a systematic review and meta-analysis. BMC Complementary Medicine and Therapies. 2021;21(1):102. — PubMed PMID: 33771151
  13. Yu C, Fan X, Li Z, Liu X, Wang G. Efficacy and safety of total glucosides of paeony combined with acitretin in the treatment of moderate-to-severe plaque psoriasis: a double-blind, randomised, placebo-controlled trial. European Journal of Dermatology. 2017;27(2):150–154. — PubMed PMID: 28400341
  14. Takeda S, Isono T, Wakui Y, et al. Absorption and excretion of paeoniflorin in rats. Journal of Pharmacy and Pharmacology. 1995;47(12A):1036–1040. — PubMed PMID: 8932691
  15. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367–378.e5. — PubMed PMID: 25865049

PubMed Topic Searches

  1. PubMed: Paeonia lactiflora and liver
  2. PubMed: Paeoniflorin and NF-κB
  3. PubMed: TGP and hepatoprotection
  4. PubMed: Anti-fibrotic natural compounds
  5. PubMed: Supplement-induced liver injury
  6. PubMed: Weight loss and liver histology in MASLD
  7. PubMed: Hepatitis C direct-acting antivirals
  8. PubMed: Paracetamol hepatotoxicity
  9. PubMed: Coffee and liver fibrosis, cirrhosis and liver cancer

Connections


Back to Table of Contents